Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Green House Holdings North America is a cannabis brand and intellectual property company established to bring Green House Brands products, genetics, trademarks, and know-how into the North American market. Public sources tie the company to a 2017 joint venture with Canopy Growth, Organa Brands, and Agripharm in Canada, under which it contributed cannabis-related proprietary technology, trademarks, genetics, and other IP. The available evidence indicates a commercial cannabis business focused on branded products and genetics rather than a traditional biotech, biopharma, or healthcare drug-development model. I did not find evidence of a clinical-stage therapeutic pipeline, regulated pharmaceutical programs, or human healthcare R&D programs attributable to this entity. As a result, it should not be classified as a life sciences/biotech/pharma company for analyst purposes.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Green House Holdings North America.